Merci d'essayer une autre recherche
L’objectif de placement fondamental du Fonds consiste à réaliser une plus-value du capital à long terme en investissant principalement dans des titres de participation de sociétés situées aux États-Unis et dans d’autres pays, et axées sur la recherche, le développement, la production ou la distribution de produits ou de services ayant trait aux soins de santé, à la médecine ou aux sciences de la vie. Les sociétés du secteur des sciences de la santé sont définies comme étant celles qui consacrent ou tirent au moins 50 % de leur actif, de leurs revenus ou de leurs produits d’exploitation des activités susmentionnées.
Nom | Titre | Depuis | Jusqu’à |
---|---|---|---|
Ziad Bakri | Equity Research Analyst | 2016 | Maintenant |
Biographie | Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban | ||
Taymour R. Tamaddon | Portfolio Manager | 2013 | 2016 |
Biographie | Taymour R. Tamaddon is a vice president of T. Rowe Price Group, Inc. and T. Rowe Price Associates, Inc. He is also a vice president of the T. Rowe Price Institutional International Funds, Inc., and the T. Rowe Price International Funds, Inc. He joined the firm in 2004 after serving as a summer intern with T. Rowe Price in 2003, covering the eye care industry. Prior to this, Taymour was employed by Amazon.com in the areas of finance and merchandizing. He was also a consultant with Booz Allen and Hamilton, specializing in the energy industry. | ||
Kris H. Jenner | Chairman | 2000 | 2012 |
Biographie | Mr. Jenner has been chairman of the committee since2000.He is a lead portfolio manager and a VP of T. Rowe Price Group. Dr. Jenner joined T. Rowe in 1997 as a health care sector analyst and now acts as its lead analyst for biotechnology and US pharmaceutical companies. He has also been portfolio manager for the Oxford Capital Group, where he managed a private hedge fund specializing in health care. Dr. Jenner graduated summa cum laude and as a member of Phi Beta Kappa from the University of Illinois with a B.S. in Chemistry. He received a D. Phil. from University of Oxford. | ||
Brian Stansky | Vice President, Investment Analyst | 1996 | 2000 |
Biographie | Stansky is a vice president with T. Rowe Price Associates, his employer since 1989. He also serves as an investment analyst in the firm's equity research division. Previously, he worked as a financial analyst with Honeywell Information Systems. Stansky is a Chartered Financial Analyst. | ||
T. Rowe Price | - | 1996 | 1998 |
Joseph Klein | Vice President | 1996 | 1998 |
Biographie | Joseph Klein is a Portfolio Manager for the Hightower Equity SMA strategies. He is responsible for the quantitative modeling and leads portfolio construction decisions made throughout the investment process. Joe has seven years of investment related experience and was previously a Leveraged Finance Credit Analyst for Barclays, where he covered health care and industrial companies. Joe also spent time as a Restructuring Senior Associate for Ankura Consulting Group, where he advised the Government of Puerto Rico in 2017-2018. Joe graduated from New York University’s Stern School of Business. Joe holds the FINRA Series 7 & 63 licenses. Outside of work, Joe interests include real estate, softball, and urban gardening. He is a lifelong New Yorker. |
Voulez-vous vraiment bloquer %USER_NAME% ?
Si vous continuez, vous et %USER_NAME% ne verrez plus vos publications Investing.com mutuelles.
%USER_NAME% a bien été ajouté à votre Liste d’utilisateurs bloqués
Vous venez de débloquer cette personne et devrez attendre 48 heures avant de la bloquer de nouveau.
Je souhaite signaler ce commentaire comme:
Merci
Le commentaire signalé sera révisé par nos modérateurs